Table 3.
Differences in the clinic-pathologic features of subungual (n = 30) and acral (n = 59) invasive melanomas.
| No. (%) | Subungual | Acral | p | |
|---|---|---|---|---|
| Sex | 0.936 | |||
| Male | 41 (46.1) | 14 (46.7) | 27 (45.8) | |
| Female | 48 (53.9) | 16 (53.3) | 32 (54.2) | |
| Age (years) | 0.054 | |||
| ≤63 | 35 (39.3) | 16 (53.3) | 19 (32.2) | |
| >63 | 54 (30.7) | 14 (46.7) | 40 (67.8) | |
| Tumor location | 0.000 | |||
| Upper | 28 (31.5) | 18 (60.0) | 10 (16.9) | |
| Lower | 61 (68.5) | 12 (40.0) | 49 (83.1) | |
| Breslow thickness | 0.528 | |||
| <1 mm | 27 (30.3) | 12 (40.0) | 15 (25.4) | |
| 1.01–2.00 mm | 15 (16.9) | 4 (13.3) | 11 (18.6) | |
| 2.01–4.00 mm | 19 (21.3) | 5 (16.7) | 14 (23.7) | |
| >4.00 mm | 39 (31.5) | 9 (30.0) | 19 (32.2) | |
| Lymph node metastasis at the time of diagnosis | 0.603 | |||
| Absent | 71 (79.8) | 23 (76.7) | 48 (81.4) | |
| Present | 18 (20.2) | 7 (23.3) | 11 (18.6) | |
| Distant metastasis at the time of diagnosis | 0.989 | |||
| Absent | 86 (96.6) | 29 (96.7) | 57 (96.6) | |
| Present | 3 (3.4) | 1 (3.3) | 2 (3.4) | |
| Stage group | 0.745 | |||
| I–II | 70 (78.7) | 23 (76.7) | 47 (79.7) | |
| III–IV | 19 (21.3) | 7 (23.3) | 12 (20.3) | |
| Immunotherapy | 0.674 | |||
| Not carried out | 59 (66.3) | 19 (63.3) | 40 (67.8) | |
| Carried out | 30 (33.7) | 11 (36.7) | 19 (32.2) | |
| Trauma | 0.004 | |||
| Absent | 85 (95.5) | 26 (86.7) | 59 (100.0) | |
| Present | 4 (4.5) | 4 (13.3) | 0 (0.0) | |
| Ulceration | 0.714 | |||
| Absent | 54 (60.7) | 19 (63.3) | 35 (59.3) | |
| Present | 35 (39.3) | 11 (36.7) | 24 (40.7) | |
| Loco-regional recurrence | 0.179 | |||
| Absent | 77 (86.5) | 28 (93.3) | 49 (83.1) | |
| Present | 12 (13.5) | 2 (6.7) | 10 (16.9) | |
| Distant metastasis during the follow-up | 0.786 | |||
| Absent | 61 (68.5) | 20 (66.7) | 41 (69.5) | |
| Present | 28 (31.5) | 10 (33.3) | 18 (30.5) |